Mike Evers, Author at ORTHOWORLD

CONMED Cites Better Market and Execution in Overperformance

The company grew 22% in 1Q23 due to improving surgical volumes and working through its warehouse-driven backlog from late-2022.

Apr 28, 2023

We tracked 32 orthopedic funding announcements in 2022, a modest slowdown after the flurry of investor activity in the wake of the pandemic.

Apr 24, 2023

Excluding the impact of currency translation, the company grew in the mid-single digits for the first quarter of 2023.

Apr 20, 2023

According to our estimates, the global orthopedic market exceeded $55 billion in sales in 2022, driven by procedure volume improvement.

Mar 31, 2023

We spoke to Enovis CEO Matt Trerotola about foundational implant technologies, ASC penetration, tech adoption and successful M&A deals.

Mar 21, 2023

The company's orthopedic sales grew in the high single digits for 2022, and it launched new cornerstone products in high-growth segments.

Mar 14, 2023

With the exception of the pandemic-ridden 2020, OrthoPediatrics has grown in excess of 20% every year since its founding.

Mar 13, 2023

The company grew in the low single digits in 2022 as international growth in its orthopedics line offset competitive pressures in spine.

Mar 10, 2023

The company captured market share in 2022, growing more than 24% through new product introductions and expanded distribution.

Mar 10, 2023

The company declined in the mid-teens during 2022 as it exits markets, fills portfolio gaps and modernizes its operations.

Mar 03, 2023